Show simple item record

dc.contributor.authorDagoglu, Nergizen_US
dc.contributor.authorCallery, Marken_US
dc.contributor.authorMoser, Jamesen_US
dc.contributor.authorTseng, Jenniferen_US
dc.contributor.authorKent, Taraen_US
dc.contributor.authorBullock, Andreaen_US
dc.contributor.authorMiksad, Rebeccaen_US
dc.contributor.authorMancias, Joseph D.en_US
dc.contributor.authorMahadevan, Ananden_US
dc.date.accessioned2016-03-01T19:48:58Z
dc.date.issued2016en_US
dc.identifier.citationDagoglu, Nergiz, Mark Callery, James Moser, Jennifer Tseng, Tara Kent, Andrea Bullock, Rebecca Miksad, Joseph D. Mancias, and Anand Mahadevan. 2016. “Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Cancer.” Journal of Cancer 7 (3): 283-288. doi:10.7150/jca.13295. http://dx.doi.org/10.7150/jca.13295.en
dc.identifier.issn1837-9664en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:25658345
dc.description.abstractObjectives: After adjuvant or definitive radiation for pancreas cancer, there are limited conventional treatment options for recurrent pancreas cancer. We explored the role of (Stereotactic Body Radiotherapy) SBRT for reirradiation of recurrent pancreas Cancer. Methods: This is a retrospective study of patients reirradiated with SBRT for recurrent pancreas cancer. All patients were deemed unresectable and treated with systemic therapy. Fiducial gold markers were used. CT simulation was performed with oral and IV contrast and patients were treated with respiratory motion tracking in the CyberknifeTM system. Results: 30 patients (17 men and 13 women) with a median age of 67 years were included in the study. The median target volume was 41.29cc. The median prescription dose was 25Gy (24-36Gy) in a median of 5 fractions prescribed to a mean 78% isodose line. The median overall survival was 14 months. The 1 and 2 year local control was 78%. The worst toxicity included 3/30(10%) Grade III acute toxicity for pain, bleeding and vomiting. There was 2/30 (7%) Grade III long-term bowel obstructions. Conclusions: SBRT can be a useful and tolerable option for patients with recurrent pancreas cancer after prior radiation.en
dc.language.isoen_USen
dc.publisherIvyspring International Publisheren
dc.relation.isversionofdoi:10.7150/jca.13295en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747882/pdf/en
dash.licenseLAAen_US
dc.subjectPancreatic Canceren
dc.subjectSBRT (Stereotactic Body Radiotherapy)en
dc.subjectReirradiationen
dc.titleStereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Canceren
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalJournal of Canceren
dash.depositing.authorBullock, Andreaen_US
dc.date.available2016-03-01T19:48:58Z
dc.identifier.doi10.7150/jca.13295*
dash.contributor.affiliatedBullock, Andrea
dash.contributor.affiliatedMiksad, Rebecca


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record